Recruiting

Observational Study

Sponsor:

CorEvitas

Code:

NCT05745389

Conditions

Alopecia Areata

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Prospective, observational cohort study for subjects with AA under the care of a dermatology provider. Approximately 5,000 subjects and 100 clinical sites in North America will be recruited to participate with no defined upper limit for either target.

Conditions

Alopecia Areata

Study ID

NCT05745389

Start date

Oct 25, 2022

Status verified date

Jan, 2026

Completion date

Dec 31, 2099

Anticipated

Primary completion date

Dec 31, 2099

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • A subject must meet all the following criteria to participate in the registry:

1. Has been diagnosed with alopecia areata by a dermatologist or a qualified dermatology practitioner.
2. Is at least 18 years of age or older.
3. Is willing to provide Personal Information.
4. Is prescribed or starting an Enrollment Eligible Medication at the time of enrollment.

Exclusion Criteria:

  • Any of the following would exclude the subject from participating in the registry:

1. Is participating or planning to participate in a double-blind randomized trial for an AA drug. Note:

Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.

Study Design

Enrollment

5000 participants

Anticipated

Interventions and Outcome Measures

Arms

Alopecia Areata

Pts presenting to enrolling sites across the US are invited to enroll if eligible

Primary outcome measure

  • Alopecia epidemiology, presentation, natural history, management, and outcomes [ Time Frame: A minimum of 10 years from last patient enrolled ]

Central Contacts and Locations

Locations

CorEvitas, LLC

Recruiting

Waltham, Massachusetts, United States, 02451

Contacts

More Information

Sponsor

CorEvitas

Last update posted

Feb 9, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by CorEvitas on 2026-02-09.